Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
S-equol in Triple Negative Breast Cancer
NCT02352025Phase 1Completed
- Sponsor
- UT Health San Antonio
- Start
- Apr 2015
- Primary completion
- Apr 2019
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of s-equol in triple-negative breast cancer (TNBC), sponsored by UT Health San Antonio. Primary endpoint: Proliferation Rate of Triple Negative Breast Cancer at 14 days. Started Apr 2015; status: completed.
02
Drugs
s-equol
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT02352025.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02352025.